The present invention relates to taxane analogs for the treatment of cancer having the general formula: ##STR00001## wherein R.sub.1 and R.sub.2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R.sub.3 is hydroxyl or OP.sub.1; R.sub.4 and R.sub.5 are each hydroxyl or R.sub.7COO; R.sub.6 is hydroxyl, OP.sub.2, R.sub.7COO, or an ether functionality; R.sub.7 is an alkyl group, an olefinic group, or an aromatic group; P.sub.1 and P.sub.2 are each hydroxyl protecting groups; R.sub.8 and R.sub.9 are each selected from H, alkyl group, olefinic or aromatic group. The present invention is also directed to production methods and intermediates useful in the formation of these new taxane analogs. The methods may begin with a starting compound, such as paclitaxel or docetaxel, which is converted into a taxane analog through various intermediate compounds.